Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
Four patients with metastatic primary small bowel adenocarcinoma associated with Crohn's disease were successfully treated with low dose combination chemotherapy consisting of 5-fluorouracil, leucovorin and irinotecan with or without gemcitabine. Benefits included prolonged survival, objective responses, response of resistant tumors, downstaging, and a successful secondary complete resection (Ro) with a durable remission.
Bruckner
H W
HW
Medical Oncology, Lutheran Medical Center, 150-55th St., Brooklyn, NY 11220, USA. HBRUCKNER@LMCMC.COM
Hrehorovich
V R
VR
Sawhney
H S
HS
Meeus
S I
SI
Coopeman
A M
AM
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D004379:Duodenal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology; D000077146:Irinotecan; D007580:Jejunal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D012074:Remission Induction; D016019:Survival Analysis
D000077146:Irinotecan; D002955:Leucovorin; D002166:Camptothecin